Inpatient Management of Tirzepatide

1. Decision to Continue or Hold Therapy

Continue tirzepatide at the current dose when the patient is eating, tolerating oral medications, and is hemodynamically stable. 1
Temporarily hold tirzepatide if the patient develops significant gastrointestinal symptoms (nausea, vomiting, diarrhea), is NPO for a procedure, or shows signs of volume depletion. 1

Tirzepatide has a long half‑life of approximately 5 days, so pharmacologic effects persist for several days after discontinuation. 2

Renal & Volume Status: Monitor serum creatinine, electrolytes (especially potassium), blood pressure, and signs of dehydration because tirzepatide can cause modest blood‑pressure reductions and increase the risk of acute kidney injury. 1, 4
Cardiovascular: Expect modest increases in heart rate and reductions in blood pressure; adjust antihypertensive therapy accordingly. 1, 4
Glycemic Control: Check blood glucose frequently, particularly if the patient is NPO or has altered dietary intake, to avoid hyper‑ or hypoglycemia. 5

Nausea, vomiting, and diarrhea are the most common adverse effects and are usually mild‑to‑moderate, especially during dose escalation. 1
Delayed gastric emptying is a notable concern that may persist with chronic use; patients should avoid eating past fullness, consume smaller, more frequent meals, and limit fatty foods. 3, 1

Hold tirzepatide for at least one dosing interval (≈ 1 week) before elective procedures requiring general anesthesia to reduce aspiration risk from delayed gastric emptying. 3
The American Society of Anesthesiologists recommends stopping weekly tirzepatide injections one week prior to procedures. 3
Perform a risk‑benefit assessment that considers procedure type, anesthetic technique, and individual patient factors. 3

Conduct comprehensive medication reconciliation at admission and at each care transition, documenting tirzepatide dose, frequency, and last administration date. 6
Adjust doses of other glucose‑lowering agents when oral intake decreases to prevent hypoglycemia. 5
At discharge, provide clear instructions to resume tirzepatide if it was held; if discontinuation exceeded one week, restart at the lowest dose (2.5 mg weekly) and re‑titrate using the standard escalation schedule (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, each for 4 weeks). 7, 1, 2

Renal Impairment: Tirzepatide can be used across CKD stages 1‑5 without dose adjustment, but enhanced monitoring of renal function and electrolytes is warranted. 3
Diabetes Management: Tirzepatide reduces HbA1c by 1.9‑2.2 % with a low risk of hypoglycemia when not combined with insulin or sulfonylureas; continue glucose monitoring and adjust concomitant diabetes medications as needed. 8, 2, 5

Restarting tirzepatide at the full maintenance dose after a prolonged hold increases the likelihood of gastrointestinal side effects. 1
Inadequate medication reconciliation can lead to dosing errors or drug interactions. 6
Ignoring aspiration risk for urgent procedures in patients on chronic tirzepatide may result in peri‑operative complications. 3